

**SAMPHIRE NEUROSCIENCE LTD
UNAUDITED ABRIDGED FINANCIAL STATEMENTS
FOR THE PERIOD 2 SEPTEMBER 2021 TO 30 SEPTEMBER 2022**

Samphire Neuroscience Ltd
Unaudited Financial Statements
For the Period 2 September 2021 to 30 September 2022

Contents

	Page
Abridged Balance Sheet	1—2
Notes to the Abridged Financial Statements	3—4

Samphire Neuroscience Ltd
Abridged Balance Sheet
As at 30 September 2022

Registered number: 13600022

	Notes	30 September 2022	
		£	£
FIXED ASSETS			
Tangible Assets	3		3,941
			<u>3,941</u>
CURRENT ASSETS			
Debtors		31,325	
Cash at bank and in hand		403,821	
		<u>435,146</u>	
Creditors: Amounts Falling Due Within One Year		<u>(15,670)</u>	
NET CURRENT ASSETS (LIABILITIES)			<u>419,476</u>
TOTAL ASSETS LESS CURRENT LIABILITIES			<u>423,417</u>
NET ASSETS			<u>423,417</u>
CAPITAL AND RESERVES			
Called up share capital	4		100
Other reserves			517,807
Profit and Loss Account			<u>(94,490)</u>
SHAREHOLDERS' FUNDS			<u>423,417</u>

Samphire Neuroscience Ltd
Abridged Balance Sheet (continued)
As at 30 September 2022

For the period ending 30 September 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

All of the company's members have consented to the preparation of an Abridged Profit and Loss Account and an Abridged Balance Sheet for the year end 30 September 2022 in accordance with section 444(2A) of the Companies Act 2006.

On behalf of the board

Mr Alexander Cook

Director

14/02/2023

The notes on pages 3 to 4 form part of these financial statements.

Samphire Neuroscience Ltd
Notes to the Abridged Financial Statements
For the Period 2 September 2021 to 30 September 2022

1. Accounting Policies

1.1. Basis of Preparation of Financial Statements

The financial statements are prepared under the historical cost convention and in accordance with the FRS 102 Section 1A Small Entities - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.

1.2. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Fixtures & Fittings	25% on cost
Computer Equipment	25% on cost

1.3. Foreign Currencies

Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.

1.4. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.

2. Average Number of Employees

Average number of employees, including directors, during the year was as follows: 2

Samphire Neuroscience Ltd
Notes to the Abridged Financial Statements (continued)
For the Period 2 September 2021 to 30 September 2022

3. Tangible Assets

	Total £
Cost	
As at 2 September 2021	-
Additions	4,449
As at 30 September 2022	4,449
Depreciation	
As at 2 September 2021	-
Provided during the period	508
As at 30 September 2022	508
Net Book Value	
As at 30 September 2022	3,941
As at 2 September 2021	-
4. Share Capital	
	30 September 2022
Allotted, Called up and fully paid	100

5. Reserves

Profit and loss account

The profit and loss account includes all current and prior period retained profits and losses.

6. General Information

Samphire Neuroscience Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 13600022 . The registered office is 85 Great Portland Street, First Floor, London, W1W 7LT.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.